Company Details
servier
12,487
476,033
3254
servier.com
0
SER_2679179
In-progress

Servier Company CyberSecurity Posture
servier.comFounded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, Eastern Europe and Brazil. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com
Company Details
servier
12,487
476,033
3254
servier.com
0
SER_2679179
In-progress
Between 750 and 799

Servier Global Score (TPRM)XXXX



No incidents recorded for Servier in 2025.
No incidents recorded for Servier in 2025.
No incidents recorded for Servier in 2025.
Servier cyber incidents detection timeline including parent company and subsidiaries

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, Eastern Europe and Brazil. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com


Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitm
EMS is the leading pharmaceutical company in Brazil. Established since 45 years and with 100% national capital, the company has two industrial plants strategically placed in São Bernardo do Campo and Hortolândia, in the state of São Paulo. With a work based on daring, simplicity, excellence and res

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving ac

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier li

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Tr
CVS Pharmacy is America’s leading retail pharmacy with more than 9,600 locations nationwide. For more than 50 years, CVS Pharmacy has offered customers the products and services they need to stay on their path to better health. In addition to our pharmacies, our stores feature on-trend beauty depart

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worl
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working t
.png)
CEO announces security and governance reforms inside the company, including the adoption of secure-by-design practices.
The Federal Fire Service's cybersecurity push aligns with the Ministry of Interior's digital reform, which requires agencies to automate...
A new guidance from U.S. and allied cybersecurity agencies has been issued for securing Microsoft Exchange servers against cyberattacks.
Google Threat Intelligence Group is investigating a series of attacks linked to a hacker targeting a critical vulnerability in Windows Server...
Microsoft has issued an out-of-band update and is urging users to immediately apply the patch.
NIS Launches 2025 Cybersecurity Campaign ... In a strategic initiative aimed at fortifying Nigeria's defences against escalating cyber threats,...
The Nigeria Immigration Service (NIS) on Thursday held its 2025 Cybersecurity Awareness Seminar with a call for stronger digital vigilance,...
In a decisive move to strengthen Nigeria's defenses against rising cyber threats, the Nigeria Immigration Service NIS has called for...
PCs cobbled together in shoeboxes, a first software sold at 14, and 27 years of loyalty to Servier: Stéphane Tournadre's path, Group Chief...

Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
The official website of Servier is https://servier.com.
According to Rankiteo, Servier’s AI-generated cybersecurity score is 785, reflecting their Fair security posture.
According to Rankiteo, Servier currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.
According to Rankiteo, Servier is not certified under SOC 2 Type 1.
According to Rankiteo, Servier does not hold a SOC 2 Type 2 certification.
According to Rankiteo, Servier is not listed as GDPR compliant.
According to Rankiteo, Servier does not currently maintain PCI DSS compliance.
According to Rankiteo, Servier is not compliant with HIPAA regulations.
According to Rankiteo,Servier is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.
Servier operates primarily in the Pharmaceutical Manufacturing industry.
Servier employs approximately 12,487 people worldwide.
Servier presently has no subsidiaries across any sectors.
Servier’s official LinkedIn profile has approximately 476,033 followers.
Servier is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.
No, Servier does not have a profile on Crunchbase.
Yes, Servier maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/servier.
As of November 27, 2025, Rankiteo reports that Servier has not experienced any cybersecurity incidents.
Servier has an estimated 5,260 peer or competitor companies worldwide.
Total Incidents: According to Rankiteo, Servier has faced 0 incidents in the past.
Incident Types: The types of cybersecurity incidents that have occurred include .
.png)
Angular is a development platform for building mobile and desktop web applications using TypeScript/JavaScript and other languages. Prior to versions 19.2.16, 20.3.14, and 21.0.1, there is a XSRF token leakage via protocol-relative URLs in angular HTTP clients. The vulnerability is a Credential Leak by App Logic that leads to the unauthorized disclosure of the Cross-Site Request Forgery (XSRF) token to an attacker-controlled domain. Angular's HttpClient has a built-in XSRF protection mechanism that works by checking if a request URL starts with a protocol (http:// or https://) to determine if it is cross-origin. If the URL starts with protocol-relative URL (//), it is incorrectly treated as a same-origin request, and the XSRF token is automatically added to the X-XSRF-TOKEN header. This issue has been patched in versions 19.2.16, 20.3.14, and 21.0.1. A workaround for this issue involves avoiding using protocol-relative URLs (URLs starting with //) in HttpClient requests. All backend communication URLs should be hardcoded as relative paths (starting with a single /) or fully qualified, trusted absolute URLs.
Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Uncontrolled Recursion vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft deep ASN.1 structures that trigger unbounded recursive parsing. This leads to a Denial-of-Service (DoS) via stack exhaustion when parsing untrusted DER inputs. This issue has been patched in version 1.3.2.
Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Integer Overflow vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft ASN.1 structures containing OIDs with oversized arcs. These arcs may be decoded as smaller, trusted OIDs due to 32-bit bitwise truncation, enabling the bypass of downstream OID-based security decisions. This issue has been patched in version 1.3.2.
Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. Prior to versions 7.0.13 and 8.0.2, working with large buffers in Lua scripts can lead to a stack overflow. Users of Lua rules and output scripts may be affected when working with large buffers. This includes a rule passing a large buffer to a Lua script. This issue has been patched in versions 7.0.13 and 8.0.2. A workaround for this issue involves disabling Lua rules and output scripts, or making sure limits, such as stream.depth.reassembly and HTTP response body limits (response-body-limit), are set to less than half the stack size.
Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. In versions from 8.0.0 to before 8.0.2, a NULL dereference can occur when the entropy keyword is used in conjunction with base64_data. This issue has been patched in version 8.0.2. A workaround involves disabling rules that use entropy in conjunction with base64_data.

Get company history
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.